KIMS Hospitals: Navigating Growth and Profitability in Q3 FY26

KIMS Hospitals, a prominent name in the Indian healthcare sector, recently unveiled its Q3 FY26 earnings, painting a picture of strategic expansion and operational resilience. The company achieved a significant milestone, recording its highest-ever consolidated revenue, surpassing the INR 1,000 crore mark for the quarter. This robust top-line performance, reflecting a 29.2% year-on-year and 3.9% quarter-on-quarter growth, underscores the effectiveness of its expanding network and inherent operational strengths, even as the third quarter is traditionally considered weaker.

Despite the impressive revenue growth, the company's consolidated EBITDA experienced a marginal decline of 0.4% year-on-year and 2% quarter-on-quarter, settling at INR 204.1 crore. This EBITDA erosion was primarily attributed to the initial operational costs and ramp-up phases of newer units commissioned over the past 9 to 12 months. Consequently, consolidated Profit Before Tax (PBT) and Profit After Tax (PAT) also saw declines of 49.0% and 43.9% year-on-year, respectively, influenced by a fair value loss on a call option, higher finance costs, and increased depreciation. The EBITDA margin stood at 20.4% for Q3 FY26, compared to 25.9% in Q3 FY25.

Operational Highlights and Strategic Initiatives

KIMS Hospitals' operational metrics demonstrated healthy growth. The Average Revenue Per Operating Bed (ARPOB) increased by 20.5% year-on-year and 10.3% quarter-on-quarter, reaching INR 46,341. Similarly, Average Revenue Per Patient (ARPP) grew by 13.9% year-on-year and 9% quarter-on-quarter, to INR 164,232. Inpatient (IP) volumes rose by 13.2% year-on-year but saw a 4.9% decline quarter-on-quarter, while Outpatient (OP) volumes increased by 24.5% year-on-year despite a 1.2% quarter-on-quarter dip. The overall occupancy stood at 49.0% for Q3 FY26.

The company's strategic focus on expanding its multi-specialty care across various geographies continues to yield results. KIMS Hospitals now operates 25 hospitals across 5 states: Andhra Pradesh, Telangana, Maharashtra, Kerala, and Karnataka, with a planned entry into Tamil Nadu (Chennai). The management highlighted several key initiatives and achievements:

• New Unit Stabilisation: Newer units like Nashik and Guntur have achieved EBITDA positive status, demonstrating successful ramp-up. Thane and Mahadevapuram in Bangalore are projected to become EBITDA positive or neutral by Q1 FY27, with Electronic City following by Q3 FY27.
• Capacity Expansion: The company is adding over 2000+ beds through greenfield projects, acquisitions, and O&M opportunities. This includes the commissioning of a new Kondapur facility in the next 3-4 months and bringing 200 renovated beds in Secunderabad online by H2 FY27.
• Advanced Medical Technology: Significant investments in modern medical technology, such as the 4-Arm HD da Vinci Robotic Surgical System, MrGFUS Focussed Ultrasound, Mako Robotic for Knee Replacement, ESWL Dornier, Tulsa-Pro System, and Gamma Knife, enhance clinical outcomes and patient experience.
• Clinical Excellence: KIMS Hospitals has achieved numerous 'firsts' in India and Asia, including the first COVID Double Lung transplant, the first hospital in South India to introduce Da Vinci Robotic System, and being a leading player in organ transplantation and neurosurgery.

Financial Summary Table (Consolidated)

Segmental Performance and Future Outlook

The company's revenue mix for 9M FY26 highlights its diverse service offerings: Cardiac Sciences (17%), Orthopaedics (14%), Neuro Sciences (11%), Mother & Child (10%), Gastric Sciences (10%), Renal Sciences (9%), Oncology (6%), Organ Transplant (2%), and Others (21%). The payer mix is predominantly Cash (53%) and Insurance (30%), with Corporate (13%) and Aarogyasri (4%) contributing the rest. This diversification helps mitigate risks associated with any single specialty or payer segment.

Geographically, Telangana remains the largest contributor to total revenue (58.3%) and EBITDA (82.6%), showcasing its mature market position. Andhra Pradesh contributes 24.6% to revenue and 27.9% to EBITDA. Newer markets like Maharashtra, Kerala, and Karnataka are in ramp-up phases, with Maharashtra showing a negative EBITDA contribution (-1.8%) in 9M FY26, indicating the ongoing investment in these regions. The management acknowledged a dip in Andhra Pradesh's IP volume due to a state government strike on Aarogyasri payments in Q3, but noted that things have bounced back in January.

Management reiterated its commitment to disciplined capital allocation. The debt numbers for the current expansion have peaked, and future expansions are planned to be funded through means other than debt, aiming for a quarter-on-quarter reduction in debt. The company's strategy of entering underserved micro-markets in larger cities like Chennai and Mumbai, coupled with its focus on turning around new units, positions it for sustained long-term growth. KIMS Hospitals aims to double its top line within three years, a target it believes it is well on track to achieve, if not exceed.

In conclusion, KIMS Hospitals' Q3 FY26 performance reflects a company in a dynamic growth phase. While the initial costs of new expansions have impacted short-term profitability, the underlying operational strength, strategic initiatives, and management's clear vision for future growth underscore its potential to continue delivering value to its stakeholders. The focus on clinical excellence, technological advancement, and geographical diversification provides a strong foundation for its journey from a regional leader to a national healthcare powerhouse.